Eurointervention最新文献

{"title":"Ultrasound-guided versus fluoroscopy-guided large-bore femoral access in PCI of complex coronary lesions: the international, multicentre, randomised ULTRACOLOR Trial.","authors":"Tom A Meijers, Alexander Nap, Adel Aminian, Thomas Schmitz, Joseph Dens, Koen Teeuwen, Jan-Peter van Kuijk, Marleen van Wely, Yoann Bataille, Adriaan O Kraaijeveld, Vincent Roolvink, Jan-Henk E Dambrink, A T Marcel Gosselink, Renicus S Hermanides, Jan Paul Ottervanger, Ioannis Tsilingiris, Deborah M F van den Buijs, Niels van Royen, Maarten A H van Leeuwen","doi":"10.4244/EIJ-D-24-00089","DOIUrl":"10.4244/EIJ-D-24-00089","url":null,"abstract":"<p><strong>Background: </strong>Transfemoral access is often used when large-bore guide catheters are required for percutaneous coronary intervention (PCI) of complex coronary lesions, especially when large-bore transradial access is contraindicated. Whether the risk of access site complications for these procedures may be reduced by ultrasound-guided puncture is unclear.</p><p><strong>Aims: </strong>We aimed to show the superiority of ultrasound-guided femoral puncture compared to fluoroscopy-guided access in large-bore complex PCI with regard to access site-related Bleeding Academic Research Consortium 2, 3 or 5 bleeding and/or vascular complications requiring intervention during hospitalisation.</p><p><strong>Methods: </strong>The ULTRACOLOR Trial is an international, multicentre, randomised controlled trial investigating whether ultrasound-guided large-bore femoral access reduces clinically relevant access site complications compared to fluoroscopy-guided large-bore femoral access in PCI of complex coronary lesions.</p><p><strong>Results: </strong>A total of 544 patients undergoing complex PCI mandating large-bore (≥7 Fr) transfemoral access were randomised at 10 European centres (median age 71; 76% male). Of these patients, 68% required PCI of a chronic total occlusion. The primary endpoint was met in 18.9% of PCI with fluoroscopy-guided access and 15.7% of PCI with ultrasound-guided access (p=0.32). First-pass puncture success was 92% for ultrasound-guided access versus 85% for fluoroscopy-guided access (p=0.02). The median time in the catheterisation laboratory was 102 minutes versus 105 minutes (p=0.43), and the major adverse cardiovascular event rate at 1 month was 4.1% for fluoroscopy-guided access and 2.6% for ultrasound-guided access (p=0.32).</p><p><strong>Conclusions: </strong>As compared to fluoroscopy-guided access, the routine use of ultrasound-guided access for large-bore transfemoral complex PCI did not significantly reduce clinically relevant bleeding or vascular access site complications. A significantly higher first-pass puncture success rate was demonstrated for ultrasound-guided access.</p><p><strong>Clinicaltrials: </strong>gov identifier: NCT04837404.</p>","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":" ","pages":"e876-e886"},"PeriodicalIF":7.6,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11228538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140923951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes and predictors of transapical transcatheter mitral valve replacement: the Tendyne Expanded Clinical Study.","authors":"Lenard Conradi, Sebastian Ludwig, Paul Sorajja, Alison Duncan, Brian Bethea, Gry Dahle, Vasilis Babaliaros, Mayra Guerrero, Vinod Thourani, Nicolas Dumonteil, Thomas Modine, Andrea Garatti, Paolo Denti, Jonathon Leipsic, Michael L Chuang, Philipp Blanke, David W Muller, Vinay Badhwar","doi":"10.4244/EIJ-D-23-00904","DOIUrl":"10.4244/EIJ-D-23-00904","url":null,"abstract":"<p><strong>Background: </strong>Transcatheter mitral valve replacement (TMVR) is a therapeutic option for patients with severe mitral regurgitation (MR) who are ineligible for conventional surgery. There are limited data on the outcomes of large patient cohorts treated with TMVR.</p><p><strong>Aims: </strong>This study aimed to investigate the outcomes and predictors of mortality for patients treated with transapical TMVR.</p><p><strong>Methods: </strong>This analysis represents the clinical experience of all patients enrolled in the Tendyne Expanded Clinical Study. Patients with symptomatic MR underwent transapical TMVR with the Tendyne system between November 2014 and June 2020. Outcomes and adverse events up to 2 years, as well as predictors of short-term mortality, were assessed.</p><p><strong>Results: </strong>A total of 191 patients were treated (74.1±8.0 years, 62.8% male, Society of Thoracic Surgeons Predicted Risk of Mortality 7.7±6.6%). Technical success was achieved in 96.9% (185/191), and there were no intraprocedural deaths. At 30-day, 1- and 2-year follow-up, the rates of all-cause mortality were 7.9%, 30.8% and 40.5%, respectively. Complete MR elimination (MR <1+) was observed in 99.3%, 99.1% and 96.3% of patients, respectively. TMVR treatment resulted in consistent improvement of New York Heart Association Functional Class and quality of life up to 2 years (both p<0.001). Independent predictors of early mortality were age (odds ratio [OR] 1.11; p=0.003), pulmonary hypertension (OR 3.83; p=0.007), and institutional experience (OR 0.40; p=0.047).</p><p><strong>Conclusions: </strong>This study investigated clinical outcomes in the full cohort of patients included in the Tendyne Expanded Clinical Study. The Tendyne TMVR system successfully eliminated MR with no intraprocedural deaths, resulting in an improvement in symptoms and quality of life. Continued refinement of clinical and echocardiographic risks will be important to optimise longitudinal outcomes.</p>","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"20 14","pages":"e887-e897"},"PeriodicalIF":7.6,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11228541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durability of transcatheter aortic valve implantation.","authors":"Julien Ternacle, Sébastien Hecht, Hélène Eltchaninoff, Erwan Salaun, Marie-Annick Clavel, Nancy Côté, Philippe Pibarot","doi":"10.4244/EIJ-D-23-01050","DOIUrl":"10.4244/EIJ-D-23-01050","url":null,"abstract":"<p><p>Transcatheter aortic valve implantation (TAVI) is now utilised as a less invasive alternative to surgical aortic valve replacement (SAVR) across the whole spectrum of surgical risk. Long-term durability of the bioprosthetic valves has become a key goal of TAVI as this procedure is now considered for younger and lower-risk populations. The purpose of this article is to present a state-of-the-art overview on the definition, aetiology, risk factors, mechanisms, diagnosis, clinical impact, and management of bioprosthetic valve dysfunction (BVD) and failure (BVF) following TAVI with a comparative perspective versus SAVR. Structural valve deterioration (SVD) is the main factor limiting the durability of the bioprosthetic valves used for TAVI or SAVR, but non-structural BVD, such as prosthesis-patient mismatch and paravalvular regurgitation, as well as valve thrombosis or endocarditis may also lead to BVF. The incidence of BVF related to SVD or other causes is low (<5%) at midterm (5- to 8-year) follow-up and compares favourably with that of SAVR. The long-term follow-up data of randomised trials conducted with the first generations of transcatheter heart valves also suggest similar valve durability in TAVI versus SAVR at 10 years, but these trials suffer from major survivorship bias, and the long-term durability of TAVI will need to be confirmed by the analysis of the low-risk TAVI versus SAVR trials at 10 years.</p>","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"20 14","pages":"e845-e864"},"PeriodicalIF":7.6,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11228542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporary omission of oral anticoagulation in atrial fibrillation patients undergoing percutaneous coronary intervention: rationale and design of the WOEST-3 randomised trial.","authors":"Ashley Verburg, Wilbert L Bor, I Tarik Küçük, José P S Henriques, Maarten A Vink, Willem-Peter T Ruifrok, Jacobus Plomp, Ton A C M Heestermans, Carl E Schotborgh, Pieter J Vlaar, Michael Magro, Sem A O F Rikken, Wout W A van den Broek, Carlos A G van Mieghem, Kristoff Cornelis, Liesbeth Rosseel, Karl S Dujardin, Bert Vandeloo, Tom Vandendriessche, Bert Ferdinande, Arnoud W J van 't Hof, Jan G P Tijssen, Ugo Limbruno, Raffaele De Caterina, Andrea Rubboli, Dominick J Angiolillo, Tom Adriaenssens, Willem Dewilde, Jurrien M Ten Berg","doi":"10.4244/EIJ-D-24-00100","DOIUrl":"10.4244/EIJ-D-24-00100","url":null,"abstract":"<p><p>The optimal antithrombotic management of atrial fibrillation (AF) patients who require oral anticoagulation (OAC) undergoing percutaneous coronary intervention (PCI) remains unclear. Current guidelines recommend dual antithrombotic therapy (DAT; OAC plus P2Y₁₂ inhibitor - preferably clopidogrel) after a short course of triple antithrombotic therapy (TAT; DAT plus aspirin). Although DAT reduces bleeding risk compared to TAT, this is counterbalanced by an increase in ischaemic events. Aspirin provides early ischaemic benefit, but TAT is associated with an increased haemorrhagic burden; therefore, we propose a 30-day dual antiplatelet therapy (DAPT; aspirin plus P2Y₁₂ inhibitor) strategy post-PCI, temporarily omitting OAC. The study aims to compare bleeding and ischaemic risk between a 30-day DAPT strategy following PCI and a guideline-directed therapy in AF patients requiring OAC. WOEST-3 (ClinicalTrials.gov: NCT04436978) is an investigator-initiated, international, open-label, randomised controlled trial (RCT). AF patients requiring OAC who have undergone successful PCI will be randomised within 72 hours after PCI to guideline-directed therapy (edoxaban plus P2Y₁₂ inhibitor plus limited duration of aspirin) or a 30-day DAPT strategy (P2Y₁₂ inhibitor plus aspirin, immediately discontinuing OAC) followed by DAT (edoxaban plus P2Y₁₂ inhibitor). With a sample size of 2,000 patients, this trial is powered to assess both superiority for major or clinically relevant non-major bleeding and non-inferiority for a composite of all-cause death, myocardial infarction, stroke, systemic embolism or stent thrombosis. In summary, the WOEST-3 trial is the first RCT temporarily omitting OAC in AF patients, comparing a 30-day DAPT strategy with guideline-directed therapy post-PCI to reduce bleeding events without hampering efficacy.</p>","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"20 14","pages":"e898-e904"},"PeriodicalIF":7.6,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11228535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immediate versus staged complete revascularisation in patients presenting with STEMI and multivessel disease.","authors":"Paola Scarparo, Jacob J Elscot, Hala Kakar, Wijnand K den Dekker, Johan Bennett, Manel Sabaté, Giovanni Esposito, Alberto Ranieri De Caterina, Bert Vandeloo, Paul Cummins, Mattie Lenzen, Joost Daemen, Salvatore Brugaletta, Eric Boersma, Nicolas M Van Mieghem, Roberto Diletti, For The BioVasc Investigators","doi":"10.4244/EIJ-D-23-00882","DOIUrl":"10.4244/EIJ-D-23-00882","url":null,"abstract":"<p><strong>Background: </strong>Complete revascularisation is supported by recent trials in patients with ST-elevation myocardial infarction (STEMI) and multivessel disease (MVD) without cardiogenic shock. However, the optimal timing of non-culprit lesion revascularisation is currently debated.</p><p><strong>Aims: </strong>This prespecified analysis of the BioVasc trial aims to determine the effect of immediate complete revascularisation (ICR) compared to staged complete revascularisation (SCR) on clinical outcomes in patients with STEMI.</p><p><strong>Methods: </strong>Patients presenting with STEMI and MVD were randomly assigned to ICR or SCR. The primary endpoint was the composite of all-cause mortality, myocardial infarction, any unplanned ischaemia-driven revascularisation, or cerebrovascular events at 1-year post-index procedure.</p><p><strong>Results: </strong>Between June 2018 and October 2021, 608 (ICR: 305, SCR: 303) STEMI patients were enrolled. No significant differences between ICR and SCR were observed at 1-year follow-up in terms of the primary endpoint (7.0% vs 8.3%, hazard ratio [HR] 0.84, 95% confidence interval [CI]: 0.47-1.50; p=0.55): all-cause mortality (2.3% vs 1.3%, HR 1.77, 95% CI: 0.52-6.04; p=0.36), myocardial infarction (1.7% vs 3.3%, HR 0.50, 95% CI: 0.17-1.47; p=0.21), unplanned ischaemia-driven revascularisation (4.1% vs 5.0%, HR 0.80, 95% CI: 0.38-1.71; p=0.57) and cerebrovascular events (1.4% vs 1.3%, HR 1.01, 95% CI: 0.25-4.03; p=0.99). At 30-day follow-up, a trend towards a reduction of the primary endpoint in the ICR group was observed (ICR: 3.0% vs SCR: 6.0%, HR 0.50, 95% CI: 0.22-1.11; p=0.09). ICR was associated with a reduction in overall hospital stay (ICR: median 3 [interquartile range {IQR} 2-5] days vs SCR: median 4 [IQR 3-6] days; p<0.001).</p><p><strong>Conclusions: </strong>Clinical outcomes at 1 year were similar for STEMI patients who had undergone ICR and those who had undergone SCR.</p>","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"20 14","pages":"e865-e875"},"PeriodicalIF":7.6,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11228540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subclinical leaflet thrombosis: should we be concerned?","authors":"George Dangas, Benjamin Bay","doi":"10.4244/EIJ-D-24-00205","DOIUrl":"10.4244/EIJ-D-24-00205","url":null,"abstract":"","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"20 14","pages":"e843-e844"},"PeriodicalIF":7.6,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11228536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TAVI in moderate aortic stenosis: the earlier the better?","authors":"Niklas Schofer, Sebastian Ludwig","doi":"10.4244/EIJ-D-24-00164","DOIUrl":"10.4244/EIJ-D-24-00164","url":null,"abstract":"","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"20 14","pages":"e840-e842"},"PeriodicalIF":7.6,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11228534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cerebrovascular events after transcatheter aortic valve implantation.","authors":"Pavan Reddy, Ilan Merdler, Itsik Ben-Dor, Lowell F Satler, Toby Rogers, Ron Waksman","doi":"10.4244/EIJ-D-23-01087","DOIUrl":"10.4244/EIJ-D-23-01087","url":null,"abstract":"<p><p>Periprocedural stroke after transcatheter aortic valve implantation (TAVI) remains a significant issue, which is associated with high morbidity, and is increasingly important as intervention shifts to younger and lower-risk populations. Over the last decade of clinical experience with TAVI, the incidence of periprocedural stroke has stayed largely unchanged, although it is prone to underreporting due to variation in ascertainment methods. The aetiology of stroke in TAVI patients is multifactorial, and changing risk profiles, differing study populations, and frequent device iterations have made it difficult to discern consistent risk factors. The objective of this review is to analyse and clarify the contemporary published literature on the epidemiology and mechanisms of neurological events in TAVI patients and evaluate potential preventive measures. This summary aims to improve patient risk assessment and refine case selection for cerebral embolic protection devices, while also providing a foundation for designing future trials focused on stroke prevention.</p>","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"20 13","pages":"e793-e805"},"PeriodicalIF":7.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141472629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug-coated balloons for acute coronary syndromes.","authors":"Bruno Scheller, Simon Eccleshall","doi":"10.4244/EIJ-E-24-00019","DOIUrl":"10.4244/EIJ-E-24-00019","url":null,"abstract":"","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"20 13","pages":"e791-e792"},"PeriodicalIF":7.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141472630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two-year outcomes of sirolimus-coated balloon angioplasty for coronary artery disease: the EASTBOURNE Registry.","authors":"Pier Pasquale Leone, Tay M Heang, Lee C Yan, Ignacio S Perez, Gianluca Caiazzo, Salvatore Geraci, Kam Jiyen, Fabrizio Tomai, Dario Buccheri, Giuseppe Seresini, Ramesh Singh, George Karavolias, Michele Cacucci, Raymundo Ocaranza, Alfonso Torres, Marco Caruso, Lorenzo Azzalini, Nicola Pesenti, Antonio Colombo, Bernardo Cortese, On Behalf Of The Eastbourne Investigators","doi":"10.4244/EIJ-D-23-00966","DOIUrl":"10.4244/EIJ-D-23-00966","url":null,"abstract":"","PeriodicalId":54378,"journal":{"name":"Eurointervention","volume":"20 13","pages":"e831-e833"},"PeriodicalIF":7.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141472634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}